George J. Morrow, an insider at Neurocrine Biosciences Inc (NBIX), made a significant move by purchasing 22,068 shares of the company on November 24, 2025. The shares were acquired at a price of $47.89 each, totaling approximately $1.06 million.
Following this transaction, Morrow now holds 22,068 shares of Neurocrine Biosciences. Such insider buying often signals confidence in a company's future prospects, as executives typically have access to non-public information about their operations.
Neurocrine Biosciences is a biotechnology firm focused on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Based in San Diego, California, the company has a market capitalization of $14.0 billion and a trailing P/E ratio of 32.81, with earnings per share at 4.19. Its portfolio includes FDA-approved products like INGREZZA and Orilissa, and it has a robust pipeline in mid-to late-phase clinical development.
While insider transactions can provide valuable insights, they should not be the sole factor in investment decisions. It's essential for investors to consider broader patterns of insider activity and other fundamental factors before making any conclusions.
Insider trades must be reported to the SEC, ensuring transparency regarding how company executives view their stock. Morrow's recent purchase adds to the growing interest in Neurocrine Biosciences, especially with upcoming earnings estimates of $1.44 per share on May 4, 2026, and $1.71 per share on July 28, 2026.